Clinical Study Results
1. Study Name
What does this summary cover?
This summary shows the main results from one clinical study. The results are only for
this study. Other studies may find different results. Researchers and health authorities
look at the results of many studies to decide which medicines work best and are safest
for patients.
Title of the Study: A Phase 3, Multicenter, Randomized, Open-label Trial to Evaluate the
Survival Benefit of Panitumumab and Best Supportive Care,
Compared to Best Supportive Care Alone, in Subjects With
Chemorefractory Wild-type KRAS Metastatic Colorectal Cancer
Brief Title: How Does Adding Vectibix to Colorectal Cancer Care Plans Compare
to Supportive Care Alone?
Protocol Number: 20100007
devorppA
EU Trial Number 2010-022951-49
Other Identifiers NCT01412957
Date of This Summary 17 August 2018
2. Who Sponsored This Study?
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799 USA
Phone (United States): +1 805-447-1000
Amgen Inc. is the sponsor of the study who manufactured Vectibix (also known as
panitumumab), the investigational medicine included in the study. Amgen would like to
thank everyone who participated in this study and feels it is important to share the results
of this study.
1